Search results
Results from the WOW.Com Content Network
"Moderna arm", [91] a non-serious skin reaction rarely seen ≈7 days after injection with the Moderna vaccine. The World Health Organization (WHO) stated that "the safety data supported a favorable safety profile" and that the vaccine's AE ( adverse event ) profile "did not suggest any specific safety concerns". [ 70 ]
In 2018, just three years after it had raised its astonishing startup funds, Moderna’s initial public offering — where people can buy shares of the company and the company earns a symbol on ...
In 2023, Moderna acquired OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, in its first acquisition. [27] In early 2023, the company in collaboration with Merck won breakthrough status from the FDA for its mRNA-4157/V940 drug candidate, a cancer vaccine. [28] [29]
The COVID-19 mRNA vaccines from Moderna and Pfizer–BioNTech had short-term efficacy rates of over 90 percent against the original SARS-CoV-2 virus. Prior to mRNA, drug trials on pathogens other than COVID-19 were not effective and had to be abandoned in the early phases of trials. The reason for the efficacy of the new mRNA vaccines is not clear.
Data from a mid-stage study in 157 patients had shown that the vaccine combination cut the risk of recurrence or death by 44% in patients with melanoma, the most deadly form of skin cancer, when ...
(Reuters) -Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in ...
On 18 December 2020, the US FDA granted an EUA for mRNA-1273, the Moderna vaccine. [26] [27] [28] Vaccine manufacturers are awaiting full approvals to name their vaccines. [117] [118] Moderna submitted a request for an EUA for mRNA-1273 to the FDA on 30 November 2020. [119] [120] On 18 December 2020, the FDA granted an EUA for the Moderna ...
Moderna's first quarter net loss of $1.18 billion was also stronger than Wall Street expectations of $1.4 billion in net losses, and the company now anticipates $4 billion in full-year sales.